Low Dose-VIS649 for Glomerulonephritis

"Unfortunately, this clinical trial detailed on the clinicaltrials.gov website is not currently recruiting any participants. Initially posted in July 2020 and updated lastly in March 2022, it has yet to begin seeking candidates. Nonetheless, there are 489 other trials actively searching for patients at present."

"Considering the Phase 2 status of Low Dose-VIS649, it received a safety score of 2. This denotes that while there is some data available to support its security, no trials have been conducted to measure efficacy."

"This medical experiment will document the efficacy of VIS649 when added to SOC therapy, over a year-long period. Primary objectives include evaluating Proteinuria levels and potential secondary outcomes may involve assessing ≥ 30% decline from baseline in uPCR, Change from baseline in 24-hour urine protein excretion, or even variation in participant's serum Ig concentrations."

"Currently, 20 different clinical trial sites have been established across the country. These locations include Columbus, Oxnard and Baton Rouge; other cities are also available for patient convenience. It is recommended that individuals select a nearby site to reduce their need to travel extensively if they choose to participate."